Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc A Pfeffer

Showing results (431-440 of 520) with videos related to

Pageof 52
Sort By:
European Journal of Heart Failure|March 2, 2006
Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunctionLars Køber, Karl Swedberg, John J V McMurray, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|January 5, 2008
Association between ADAMTS1 matrix metalloproteinase gene variation, coronary heart disease, and benefit of statin therapyMarc S Sabatine, Lynn Ploughman, Katy L Simonsen, et al.
The New England Journal of Medicine|December 3, 2015
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary SyndromeMarc A Pfeffer, Brian Claggett, Rafael Diaz, et al.
The New England Journal of Medicine|September 17, 2010
Erythropoietic response and outcomes in kidney disease and type 2 diabetesScott D Solomon, Hajime Uno, Eldrin F Lewis, et al.
European Heart Journal|March 1, 2008
Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT studyEldrin F Lewis, Eric J Velazquez, Scott D Solomon, et al.
Journal of the American College of Cardiology|March 5, 2021
Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal FunctionIris E Beldhuis, Peder L Myhre, Michael Bristow, et al.
Journal of the American Society of Nephrology : JASN|June 3, 2005
Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy TrialTomas Berl, Lawrence G Hunsicker, Julia B Lewis, et al.
European Journal of Heart Failure|June 27, 2024
Cardiovascular-kidney-metabolic overlap in heart failure with preserved ejection fraction: Cardiac structure and function, clinical outcomes, and response to sacubitril/valsartan in PARAGON-HFMats C H Lassen, John W Ostrominski, Brian L Claggett, et al.
The New England Journal of Medicine|November 12, 2003
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or bothMarc A Pfeffer, John J V McMurray, Eric J Velazquez, et al.
Journal of the American College of Cardiology|January 29, 2008
Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trialsOlga A Iakoubova, Carmen H Tong, Charles M Rowland, et al.
Pageof 52

Showing results (431-440 of 520) with videos related to

Sort By:
Pageof 52
European Journal of Heart Failure|March 2, 2006
Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunctionLars Køber, Karl Swedberg, John J V McMurray, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|January 5, 2008
Association between ADAMTS1 matrix metalloproteinase gene variation, coronary heart disease, and benefit of statin therapyMarc S Sabatine, Lynn Ploughman, Katy L Simonsen, et al.
The New England Journal of Medicine|December 3, 2015
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary SyndromeMarc A Pfeffer, Brian Claggett, Rafael Diaz, et al.
The New England Journal of Medicine|September 17, 2010
Erythropoietic response and outcomes in kidney disease and type 2 diabetesScott D Solomon, Hajime Uno, Eldrin F Lewis, et al.
European Heart Journal|March 1, 2008
Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT studyEldrin F Lewis, Eric J Velazquez, Scott D Solomon, et al.
Journal of the American College of Cardiology|March 5, 2021
Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal FunctionIris E Beldhuis, Peder L Myhre, Michael Bristow, et al.
Journal of the American Society of Nephrology : JASN|June 3, 2005
Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy TrialTomas Berl, Lawrence G Hunsicker, Julia B Lewis, et al.
European Journal of Heart Failure|June 27, 2024
Cardiovascular-kidney-metabolic overlap in heart failure with preserved ejection fraction: Cardiac structure and function, clinical outcomes, and response to sacubitril/valsartan in PARAGON-HFMats C H Lassen, John W Ostrominski, Brian L Claggett, et al.
The New England Journal of Medicine|November 12, 2003
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or bothMarc A Pfeffer, John J V McMurray, Eric J Velazquez, et al.
Journal of the American College of Cardiology|January 29, 2008
Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trialsOlga A Iakoubova, Carmen H Tong, Charles M Rowland, et al.
Pageof 52